Self-assembled drug delivery systems. Part 3. In vitro/in vivo studies of the self-assembled nanoparticulates of cholesteryl acyl didanosine

International Journal of Pharmaceutics

Volumn 368, Issue 1-2, 2009, Pages 207-214

  Jin, Yiguang ^a,b   Ai, Ping ^a,c   Xin, Rui ^a,b   Tian, Ying ^a   Dong, Junxing ^a   Chen, Dawei ^c   Wang, Wei ^b  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b HENAN UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Degradation; Derivative; Didanosine; Nanoparticulates; Prodrugs; Self assembly

Indexed keywords

CHOLESTERYL ADIPOYL DIDANOSINE; CHOLESTERYL SUCCINYL DIDANOSINE; DIDANOSINE; HYPOXANTHINE; NANOPARTICLE; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG STABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER HOMOGENATE; NONHUMAN; PH; PRECIPITATION; PRIORITY JOURNAL; RAT; SELF ASSEMBLED DRUG DELIVERY SYSTEM;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHOLESTEROL; DIDANOSINE; DOGS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MICE; NANOSTRUCTURES; NANOTECHNOLOGY; PARTICLE SIZE; PRODRUGS; RABBITS; RATS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 58949094512     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.10.009     Document Type: Article

References (36)

1. Aquaro S., Caliò R., Balzarini J., Bellocchi M.C., Garaci E., and Perno C.F. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 55 (2002) 209-225
2. Aquaro S., Wedgwood O., Yarnold C., Cahard D., Pathinara R., McGuigan C., Calio R., Clercq E.D., Balzarini J., and Perno C.F. Activities of masked 2′,3′-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages. Antimicrob. Agents Chemother. 44 (2000) 173-177
3. Bangham A.D., Standish M.M., and Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13 (1965) 238-252
4. Bekers O., Beijnen J., Tank M.K., Burger D., Meenhorst P., Lombarts A., and Underberg W. 2′,3′-Dideoxyinosine (ddI): its chemical stability and cyclodextrin complexation in aqueous media. J. Pharm. Biomed. Anal. 11 (1993) 489-493
5. Bodor N., and Buchwald P. Soft drug design: general principles and recent applications. Med. Res. Rev. 20 (2000) 58-101
6. Dipali S.R., Lin Y.-J., Ravis W.R., and Betageri G.V. Pharmacokinetics and tissue distribution of long circulating liposomal formulation of 2′,3′-dideoxyinosine. Int. J. Pharm. 152 (1997) 89-97
7. Faulds D., and Brogden R.N. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44 (1992) 94-116
8. Göppert T.M., and Müller R.H. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm. 60 (2005) 361-372
9. Harvie P., Desormeaux A., Bergeron M.C., Tremblay M., Beauchamp D., Poulin L., and Bergeron M.G. Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′,3′-dideoxyinosine. Antimicrob. Agents Chemother. 40 (1996) 225-229
10. Hasegawa T., and Kawaguchi T. Future of prodrugs in antiviral therapy. Clin. Pharmacokinet. 27 (1994) 331-336
11. Hecker S.J., and Erion M.D. Prodrugs of phosphates and phosphonates. J. Med. Chem. 51 (2008) 2328-2345
12. Ionescu C., and Caira M.R. Drug Metabolism: Current Concepts (2006), Springer, Dordrecht
13. Ishida T., Harashima H., and Kiwada H. Liposome clearance. Biosci. Rep. 22 (2002) 197-224
14. Jain S.K., Gupta Y., Jain A., Saxena A.R., Khare P., and Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 4 (2008) 41-48
15. Jemal M., and Hawthorne D.J. Quantitative determination of BMS-186716, a thiol compound in rat plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after hydrolysis of the methyl acrylate adduct by the native esterases. J. Chromatogr. B 698 (1997) 123-132
16. Jin Y. Nanotechnology in pharmaceutical manufacturing. In: Gad S.C. (Ed). Pharmaceutical Manufacturing Handbook: Prodruction and Processes (2008), John Wiley & Sons Inc., Hoboken, New Jersey 1249-1288
17. Jin Y., Ai P., Xin R., and Chen D. Morphological transformation of self-assembled nanostructures prepared from cholesteryl acyl didanosine and the optimal formulation of nanoparticulate systems: effects of solvents, acyl chain length and poloxamer 188. J. Colloid Interface Sci. 326 (2008) 275-282
18. Jin Y., Qiao Y., Li M., Ai P., and Hou X. Langmuir monolayers of the long-chain alkyl derivatives of a nucleoside analogue and the formation of self-assembled nanoparticles. Colloids Surf., B Biointerfaces 42 (2005) 45-51
19. Jin Y., Tong L., Ai P., Li M., and Hou X. Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN). Int. J. Pharm. 309 (2006) 199-207
20. Jin Y., Xin R., Ai P., and Chen D. Self-assembled drug delivery systems. 2. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation. Int. J. Pharm. 350 (2008) 330-337
21. Kang H.J.K., Wientjes M.G., and Au J.L.S. Tissue pharmacokinetics of 2′3′-dideoxyinosine in rats. Biochem. Pharmacol. 48 (1994) 2109-2116
22. Kawaguchi T., Hasegawa T., Seki T., Juni K., Morimoto Y., Miyakawa A., and Saneyoshi M. Prodrugs of 2′,3′-dideoxyinosine (ddI): improved oral bioavailability via hydrophobic esters. Chem. Pharm. Bull. 40 (1992) 1338-1340
23. Kawaguchi T., Suzuki Y., Nambu N., and Nagai T. Specificity of esterases and structures of prodrug esters. III. Activity of rat tissue homogenates, rat plasma and porcine liver esterase for the hydrolysis of 3′,5′-bis-dicarboxylic acid hemiesters of 5-fluoro-2′-deoxyuridine. Chem. Pharm. Bull. 33 (1985) 2956-2961
24. Lalanne M., Andrieux K., Paci A., Besnard M., Re M., Bourgaux C., Ollivon M., Desmaele D., and Couvreur P. Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. Int. J. Pharm. 344 (2007) 62-70
25. Lalanne M., Paci A., Andrieux K., Dereuddre-Bosquet N., Clayette P., Deroussent A., Re M., Vassal G., Couvreur P., and Desmaele D. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg. Med. Chem. Lett. 17 (2007) 2237-2240
26. Manouilov K.K., Xu Z.S., Boudinot F.D., Schinazi R.F., and Chu C.K. Lymphatic targeting of anti-HIV nucleosides: distribution of 2′,3′-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice. Antiviral Res. 34 (1997) 91-99
27. Minagawa T., Kohno Y., Suwa T., and Tsuji A. Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem. Pharmacol. 17 (1995) 1361-1365
28. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
29. Morris-Natschke S.L., Ishaq K.S., and Kucera L.S. Phospholipid analogs against HIV-1 infection and disease. Curr. Pharm. Des. 9 (2003) 1441-1451
30. Natarajan R., Ghosh S., and Grogan W.M. Catalytic properties of the purified rat hepatic cytosolic cholesteryl ester hydrolase. Biochem. Biophys. Res. Comm. 225 (1996) 413-419
31. Periti P., Mazzei T., and Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin. Pharmacokinet. 41 (2002) 485-504
32. Redhead H.M., Davis S.S., and Illum L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Controlled Release 70 (2001) 353-363
33. Ren S., Park M.-J., Sah H., and Lee B.-J. Effect of pharmaceutical excipients on aqueous stability of rabeprazole sodium. Int. J. Pharm. 350 (2008) 197-204
34. Shao Z., Park G.B., Krishnamoorthy R., and Mitra A.K. The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2′-ester prodrugs. Pharm. Res. 11 (1994) 237-242
35. Stolnik S., Daudali B., Arien A., Whetstone J., Heald C.R., Garnett M.C., Davis S.S., and Illum L. The effect of surface coverage and conformation of poly(ethylene oxide) (PEO) chains of poloxamer 407 on the biological fate of model colloidal drug carriers. Biochim. Biophys. Acta 1514 (2001) 261-279
36. Torchilin V.P. Nanoparticulates as Drug Carriers (2006), Imperial College Press, London